Suppr超能文献

MVE-II用于转移性恶性黑色素瘤的II期试验。

Phase II trial of MVE-II in metastatic malignant melanoma.

作者信息

Rinehart J, LaForge J, Gochnour D, Neidhart J

出版信息

Cancer Immunol Immunother. 1987;24(3):244-6. doi: 10.1007/BF00205637.

Abstract

MVE-II, a low molecular weight fraction of pyran copolymer was utilized in a Phase II trial in patients with metastatic malignant melanoma. A total of 15 patients were investigated and no clinical responses or immunologic responses were observed. We concluded that MVE-II is not an active agent in malignant melanoma.

摘要

MVE-II,一种吡喃共聚物的低分子量组分,被用于转移性恶性黑色素瘤患者的II期试验。共对15名患者进行了研究,未观察到临床反应或免疫反应。我们得出结论,MVE-II在恶性黑色素瘤中不是一种活性药物。

相似文献

本文引用的文献

6
The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy.
Cancer Invest. 1986;4(1):29-42. doi: 10.3109/07357908609039825.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验